Hers GLP-1 Program: Structure, Eligibility, and Medication

This review is part of the PlexusDx Education Hub, a resource covering GLP-1 therapies, weight-management protocols, and the genetic variables that influence how any program performs. Browse all Peptides & GLP-1 education

An independent editorial review. PlexusDx has no commercial relationship with Hers or its parent company, and no affiliate links or compensation are involved.

Hers is one of many telehealth programs offering GLP-1 support. This review walks through the structure of that offering, from intake and eligibility to how a prescription is written and filled, and finishes with the genetic groundwork underneath any GLP-1 decision. Fair-balance framing, not a buying recommendation. Current as of April 2026.

How the Hers GLP-1 offering is organized

Hers, the women's brand of Hims & Hers Health, delivers its GLP-1 support as subscription telehealth. In practice that means a licensed provider evaluates you remotely and, if you meet the program's criteria, issues a prescription that a pharmacy fills, with follow-up over time. The specific compounds, eligibility rules, and pricing are maintained on Hers's official website.

From intake to prescription

The workflow is consistent across programs of this type: you complete an intake covering weight, medical history, and current medications; a clinician reviews it and, where eligibility is met, writes a prescription; the order is routed to a retail pharmacy for an FDA-approved brand product or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide; and follow-up visits support dose titration and side-effect management. Programs differ mainly in provider type, pharmacy partner, and subscription packaging.

What the GLP-1 evidence establishes

The GLP-1 category rests on two mechanisms: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide. The pivotal programs are public, the STEP trials for semaglutide in weight management (The New England Journal of Medicine, 2021), SURMOUNT for tirzepatide in weight management (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024). Populations and endpoints vary, and individual results vary.

Access and pricing for the program

Hers publishes its GLP-1 pricing on its own site. What you pay depends on the compound, the subscription tier, and whether dispensing runs through a retail or compounding pharmacy. Across the telehealth GLP-1 market as of April 2026, monthly totals generally range from roughly $200 to $700+, with wide variance. Check current numbers at Hers's official website before committing.

The genetic groundwork beneath any GLP-1

A prescription tells a clinician what to prescribe, not the terrain they are prescribing into. Telehealth programs like this one do not examine the upstream genetic architecture that shapes every GLP-1 response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene, the direct target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion) map the baseline metabolic terrain any compound acts on. These are pathway-level markers. They do not predict response to a specific medication, but they describe the biology a clinician is prescribing into, context a prescription alone never captures.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What distinguishes the approach is that upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Reading that profile alongside the protocol is the test before you invest approach, turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx GLP-1 approach: see the Weight Management Protocols, semaglutide and tirzepatide paired with the genetic context most telehealth programs omit. Or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions About the Hers GLP-1 Program

What GLP-1 options does Hers provide?

The specific compounds offered are set by the program and posted on its own site. In general, telehealth GLP-1 programs prescribe either FDA-approved brand products or compounded semaglutide or tirzepatide, depending on eligibility and the pharmacy pathway a program uses. Verify current options directly with the brand.

Does Hers prescribe brand or compounded GLP-1?

Programs in this model route prescriptions to a retail pharmacy for FDA-approved brand products or to a 503A compounding pharmacy for compounded preparations. Which pathway applies depends on eligibility and availability, so confirm the dispensing route before assuming a particular product or price.

Who is eligible for a GLP-1 prescription?

Eligibility is decided by a licensed clinician who reviews your intake, including weight, medical history, and current medications. Only if you meet the program's criteria is a prescription issued. Telehealth evaluation replaces an in-person visit but not the clinical judgment behind prescribing.

How do genes shape a GLP-1 response?

Variants in FTO, MC4R, and TCF7L2 describe baseline appetite, energy-balance, and GLP-1 receptor biology. They are pathway-level markers that do not predict response to a specific drug, but they add context that a prescription alone, from any GLP-1 program, does not capture.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education